Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Foss

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Anesthesia and Analgesia|December 1, 1994
Premedication with oral and transdermal clonidine provides safe and efficacious postoperative sympatholysisJ E Ellis, G Drijvers, S Pedlow, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 7, 2020
Interleukin-17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosisA Wang, N Hornick, Y Lim, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 12, 2020
Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasisN Hornick, A Wang, Y Lim, et al.
American Journal of Hematology|July 24, 2018
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 studyIan W Flinn, Manish Patel, Yasuhiro Oki, et al.
Blood|January 15, 1998
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2C F LeMaistre, M N Saleh, T M Kuzel, et al.
Journal of the American Academy of Dermatology|July 23, 1998
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesM N Saleh, C F LeMaistre, T M Kuzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2015
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaS Horwitz, B Coiffier, F Foss, et al.
Annals of the New York Academy of Sciences|October 12, 2001
The role for interleukin-12 therapy of cutaneous T cell lymphomaA H Rook, M H Zaki, M Wysocka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 17, 2021
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trialR A Cowan, J J Scarisbrick, P L Zinzani, et al.
Blood|December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesIan W Flinn, Susan O'Brien, Brad Kahl, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Anesthesia and Analgesia|December 1, 1994
Premedication with oral and transdermal clonidine provides safe and efficacious postoperative sympatholysisJ E Ellis, G Drijvers, S Pedlow, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 7, 2020
Interleukin-17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosisA Wang, N Hornick, Y Lim, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 12, 2020
Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasisN Hornick, A Wang, Y Lim, et al.
American Journal of Hematology|July 24, 2018
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 studyIan W Flinn, Manish Patel, Yasuhiro Oki, et al.
Blood|January 15, 1998
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2C F LeMaistre, M N Saleh, T M Kuzel, et al.
Journal of the American Academy of Dermatology|July 23, 1998
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesM N Saleh, C F LeMaistre, T M Kuzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2015
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaS Horwitz, B Coiffier, F Foss, et al.
Annals of the New York Academy of Sciences|October 12, 2001
The role for interleukin-12 therapy of cutaneous T cell lymphomaA H Rook, M H Zaki, M Wysocka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 17, 2021
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trialR A Cowan, J J Scarisbrick, P L Zinzani, et al.
Blood|December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesIan W Flinn, Susan O'Brien, Brad Kahl, et al.
Pageof 8